Biopharmaceutical company
Appears in 1 story
Developer of mitapivat and sponsor of the RISE UP trial
A global phase 3 trial published in The Lancet found that mitapivat, an oral pyruvate kinase activator, raised hemoglobin in 41% of sickle cell disease patients, versus 3% on placebo. The drug missed its other primary endpoint: annualized pain crises fell from 3.1 to 2.6 per year, a gap that did not reach statistical significance.
Updated 2 hours ago
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
